Aterian Investment Partners, a private equity firm, completed the acquisition of Contract Pharmaceuticals, a North American contract development and manufacturing organization of non-sterile liquid and semi-solid dosage forms. Financial terms were not disclosed. “With Aterian’s backing, we are laser focused on innovation, growth and delighting our customers to further expand our unmatched position in the non-sterile liquid and topical drug products space. This collaboration undoubtedly strengthens our positioning in serving our customers and being the trusted partner to pharmaceutical companies around the world," Jan Sahai, Contract Pharmaceuticals CEO.